Dilemma of first line regimens in metastatic pancreatic adenocarcinoma


Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in… (More)
DOI: 10.3748/wjg.v22.i46.10124


3 Figures and Tables